Liraglutide and obesity: a review of the data so far

@inproceedings{Ladenheim2015LiraglutideAO,
  title={Liraglutide and obesity: a review of the data so far},
  author={Ellen Elizabeth Ladenheim},
  booktitle={Drug design, development and therapy},
  year={2015}
}
The prevalence of obesity worldwide has nearly doubled since 1980 with current estimates of 2.1 billion in 2013. Overweight and obesity lead to numerous adverse conditions including type 2 diabetes, cardiovascular disease, stroke, and certain cancers. The worldwide spread of obesity and associated comorbidities not only threatens quality of life but also presents a significant economic burden. While bariatric surgery has proven to be a viable treatment option for the morbidly obese, there is… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 22 CITATIONS

Liraglutide modulates gut microbiota and reduces NAFLD in obese mice.

  • The Journal of nutritional biochemistry
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 92 REFERENCES

The physiology of glucagon-like peptide 1

JJ Holst
  • Physiol Rev
  • 2007
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

Updates in weight loss surgery and gastrointestinal peptides.

  • Current opinion in endocrinology, diabetes, and obesity
  • 2015
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

Anxiety and depression levels in prepubertal obese children: a case-control study

  • Neuropsychiatric disease and treatment
  • 2014
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist

  • Diabetes therapy : research, treatment and education of diabetes and related disorders
  • 2014
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

Update on obesity pharmacotherapy.

  • Annals of the New York Academy of Sciences
  • 2014
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…